The development is expected to boost both the company’s Transcatheter Aortic Valve Replacement (“TAVR ... premium RESILIA portfolio, including INSPIRIS, MITRIS and KONECT.

Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS).

As in the SMART trial, early hemodynamic differences have yet to result in a clinical impact—but it may just be a matter of ...

This can be an important add-on to echocardiography in patients with a borderline need for intervention, researchers say.

Meril Life Sciences today announced one-year results from a pivotal trial evaluating its balloon-expandable Myval THV system.

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis early in the disease process while patients still had no symptoms or other ...